Magnesiumsulfaat Kalceks (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases magnesium ions that serve as cofactors for many enzymatic reactions, help regulate calcium entry into cells, and stabilize cell membranes. By competing with calcium, it reduces neuronal excitability, relaxes smooth muscle, and modulates cardiac electrical activity, which together correct magnesium deficiency and prevent hyperexcitability.

The dosage of Magnesiumsulfaat Kalceks is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and serum magnesium levels. The prescriber will select the appropriate concentration, route (intravenous, intramuscular, or subcutaneous), and infusion rate to achieve therapeutic goals while avoiding toxicity.

Magnesium sulfate is commonly used in pregnancy, especially for eclampsia and pre‑eclampsia, because it crosses the placenta and can protect the fetus. However, its use should be guided by a healthcare professional who will monitor maternal and fetal status. Limited data are available for breastfeeding, so a clinician should assess risk versus benefit.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain if needed), and assists with import documentation.

Magnesiumsulfaat Kalceks is a sterile injectable form of magnesium sulfate, offering rapid bioavailability for acute correction of magnesium deficiency and obstetric emergencies. Oral magnesium salts, such as magnesium oxide, are slower to act and are typically used for chronic supplementation. The injectable route allows precise dosing and immediate therapeutic effect, which oral forms cannot provide.

The product should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken vigorously. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles. Follow local regulations for handling injectable medicines.

Magnesiumsulfaat Kalceks is administered by a healthcare professional via intramuscular, intravenous, or subcutaneous injection. The route and infusion rate are selected based on the clinical indication, patient’s condition, and monitoring requirements. Continuous cardiac and blood pressure monitoring is recommended during intravenous administration, especially in high‑risk patients.

Serious risks include severe hypermagnesemia leading to respiratory depression, cardiac arrest, profound hypotension, and neuromuscular blockade causing paralysis. These events are more likely in patients with renal failure, excessive dosing, or when combined with other magnesium‑containing products. Prompt recognition and supportive measures are essential to mitigate these risks.

Magnesiumsulfaat Kalceks should be avoided in patients with known hypersensitivity to magnesium sulfate, severe renal impairment without appropriate monitoring, and in those with existing heart block or severe hypotension unless benefits outweigh risks. Clinicians must evaluate each patient’s medical history before initiating therapy.